Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
B8Fk | Xetra | EUR | Delayed | |
B8Fk | TradeGate | EUR | Delayed | |
B8Fk | Frankfurt | EUR | Delayed |
For the three months ended 31 March 2022, Biofrontera AG revenues increased 20% to EUR6.6M. Net loss increased from EUR4.9M to EUR28.1M. Revenues reflect United States (Country) segment increase of 25% to EUR4.8M, Europe (Region) segment increase from EUR265K to EUR637K. Higher net loss reflects Research and development costs increase of 22% to EUR1.6M (expense), Other Income decrease of 65% to EUR78K (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 6.57 | 10.31 | 5.38 | 7.62 |
Gross Profit | 5.46 | 9.11 | 4.68 | 6.5 |
Operating Income | 1.09 | 36.8 | -4.75 | -3.42 |
Net Income | -28.1 | 52.99 | -5.8 | -4 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 45.05 | 76.7 | 69.23 | 72.63 |
Total Liabilities | 15.14 | 18.7 | 53.33 | 51.06 |
Total Equity | 29.91 | 58 | 15.89 | 21.57 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 12 Months | 0 Months | 6 Months |
Cash From Operating Activities | 30.44 | -5.62 | ||
Cash From Investing Activities | -42.26 | -0.29 | ||
Cash From Financing Activities | 2.18 | 21.76 | ||
Net Change in Cash | -9.64 | 16.08 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review